Xencor (XNCR) Stock Price, News & Analysis

Company Overview

Xencor, Inc. is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics. Xencor’s pipeline features multiple clinical-stage candidates, including bispecific molecules that recruit T cells to tumor cells and antibody therapeutics targeting checkpoint pathways. The company also explores next-generation cytokine fusions designed to improve safety and efficacy profiles over conventional formats.

In advancing its discovery programs, Xencor has established strategic collaborations and licensing agreements with several leading pharmaceutical companies. Partners include Amgen, Pfizer, AstraZeneca and Lilly, among others, which leverage Xencor’s XmAb® platform to generate novel candidates across oncology, inflammation and immunology. Through these partnerships, Xencor’s technology reaches global markets via co-development and commercial licensing arrangements.

Founded in 1997 and headquartered in Monrovia, California, Xencor is led by President and Chief Executive Officer Bassil Dahiyat, Ph.D., who co-founded the company with a vision to harness protein engineering for therapeutic innovation. Over its history, Xencor has grown from a technology-focused startup into a specialized biotech organization advancing multiple clinical programs toward regulatory milestones.

Key Stats

• Today's Range: $11.20 to $11.62
• 50-Day Range: $10.41 to $13.10
• 52-Week Range: $6.92 to $18.69
• Volume: 522,184 shs
• Average Volume: 831,404 shs
• Market Capitalization: $838.55 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $24.50
• Consensus Rating: Hold

Xencor Stock Analysis - MarketRank™

Xencor scored higher than 45% of companies evaluated by MarketBeat, and ranked 607th out of 866 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Hold

Consensus Rating

Xencor has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on no strong buy ratings, 6 buy ratings, 2 hold ratings, and 2 sell ratings.

Upside Potential

Xencor has a consensus price target of $24.50, representing about 116.6% upside from its current price of $11.31.

Amount of Analyst Coverage

Xencor has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Xencor are expected to grow in the coming year, from ($3.82) to ($3.16) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Xencor is -4.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Xencor is -4.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Xencor has a P/B Ratio of 1.63. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

14.98% of the float of Xencor has been sold short.

Short Interest Ratio / Days to Cover

Xencor has a short interest ratio ("days to cover") of 15.62, which indicates bearish sentiment.

Change versus previous month

Short interest in Xencor has recently increased by 2.11%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Xencor does not currently pay a dividend.

Dividend Growth

Xencor does not have a long track record of dividend growth.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: 0.88

News Sentiment

Xencor has a news sentiment score of 0.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Xencor this week, compared to 3 articles on an average week.

Search Interest

Only 2 people have searched for XNCR on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Xencor to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.9 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Xencor insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $499,817.00 in company stock.

Percentage Held by Insiders

4.76% of the stock of Xencor is held by insiders.

Percentage Held by Institutions

Xencor has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 5/06/2026
• Today: 5/23/2026
• Next Earnings (Estimated): 8/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:XNCR
• CIK: 1326732
• Web: www.xencor.com
• Phone: (626) 305-5900
• Fax: 626-305-0350
• Employees: 280
• Year Founded: 1997

Price Target and Rating

• Average Price Target for Xencor: $24.50
• High Price Target: $42.00
• Low Price Target: $12.00
• Potential Upside/Downside: +116.6%
• Consensus Rating: Hold
• Rating Score (0-4): 2.40
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.29)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$91.92 million
• Net Margins: -177.10%
• Pretax Margin: -174.61%
• Return on Equity: -28.77%
• Return on Assets: -20.52%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.57
• Quick Ratio: 6.57

Sales & Book Value

• Annual Sales: $97.36 million
• Price / Sales: 8.61
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.95 per share
• Price / Book: 1.63

Miscellaneous

• Outstanding Shares: 74,142,000
• Free Float: 70,613,000
• Market Cap: $838.55 million
• Optionable: Optionable
• Beta: 0.93